Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 3/20 | 0.44 |
| ▸ | CCND1 | P24385 | 3/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | ICMT | O60725 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14155057 | 0.95 | HTR2C (0.55) | HTR2CHTR2AHTR7P2RX7CDK4 | |
| SCHEMBL8435460 | 0.90 | HTR2C (0.59) | HTR2CHTR2AHTR7P2RX7CDK4 | |
| SCHEMBL18856954 | 0.87 | HTR2C (0.56) | HTR2CHTR2AHTR7P2RX7CDK4 | |
| SCHEMBL5235415 | 0.83 | HTR2C (0.56) | HTR2CHTR2AHTR7P2RX7CDK4 | |
| SCHEMBL5635097 | 0.83 | HTR2C (0.53) | HTR2CHTR2AHTR7P2RX7CDK4 | |
| SCHEMBL12605578 | 0.82 | HTR2C (0.63) | HTR2CHTR2AHTR7P2RX7 | |
| SCHEMBL18856949 | 0.82 | HTR2A (0.55) | HTR2CHTR2AP2RX7CDK4CCND1 | |
| SCHEMBL5237341 | 0.82 | HTR2C (0.55) | HTR2CHTR2AHTR7P2RX7CDK4 | |
| SCHEMBL5792293 | 0.82 | P2RX7 (0.53) | HTR2CHTR2AHTR7P2RX7CDK4 | |
| SCHEMBL9994959 | 0.82 | P2RX7 (0.53) | HTR2CHTR2AHTR7P2RX7CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2A 2/4885HTR7 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.